Literature DB >> 6161715

Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

J J Gullo, C L Litterst, P J Maguire, B I Sikic, D F Hoth, P V Woolley.   

Abstract

The pharmacokinetics of cis-dichlorodiam-minoplatinum (II) (cisplatin) have been studied in seven patients, of whom four received the drug as a one hour infusion and three received it as a 20 h infusion. The patients receiving the drug over one hour exhibited biphasic clearance of total platinum with a rapid initial phase (8.7-22.5 min) and a prolonged second phase (30.5-106 h). Free (ultrafilterable) cisplatin was readily detectable in this group and was rapidly cleared (half-life about 22 min). The volume of distribution of the drug was 50.3-65.6 liters and it was 26.6-50% excreted in the urine in 48 h. In the patients receiving the 20 h infusion, a more complex plasma elimination curve was seen, with the appearance of a secondary peak. Free drug was not detectable in these patients and they showed less urinary excretion (21.4-25.9% at 48 h) than the one hour group. Cisplatin was bound to several plasma proteins, including albumin, transferrin, and gamma-globulin. The data indicate that cisplatin is retained in the body more extensively after a 20 h infusion than after a one hour infusion.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6161715     DOI: 10.1007/BF00578558

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.

Authors:  A F LeRoy; M L Wehling; H L Sponseller; W S Friauf; R E Solomon; R L Dedrick; C L Litterst; T E Gram; A M Guarino; D A Becker
Journal:  Biochem Med       Date:  1977-10

2.  Binding of platinum to human transferrin.

Authors:  R Stjernholm; F W Warner; J W Robinson; E Ezekiel; N Katayama
Journal:  Bioinorg Chem       Date:  1978-09

3.  Renal parenchymal accumulation of aminoglycoside antibiotics in rats.

Authors:  F C Luft; S A Kleit
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

4.  The antitumor agent cis-Pt(NH 3 ) 2 Cl 2 : distribution studies and dose calculations for 193m Pt and 195m Pt.

Authors:  R C Lange; R P Spencer; H C Harder
Journal:  J Nucl Med       Date:  1973-04       Impact factor: 10.057

5.  Distribution of cis-platin in blood.

Authors:  R C Manaka; W Wolf
Journal:  Chem Biol Interact       Date:  1978-09       Impact factor: 5.192

6.  Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man.

Authors:  T F Patton; K J Himmelstein; R Belt; S J Bannister; L A Sternson; A J Repta
Journal:  Cancer Treat Rep       Date:  1978-09

7.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

8.  Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat.

Authors:  B E Dahlström; L K Paalzow
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

9.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

10.  High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.

Authors:  D M Hayes; E Cvitkovic; R B Golbey; E Scheiner; L Helson; I H Krakoff
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

View more
  48 in total

1.  Chemical reactivity of cisplatin bound to human plasma proteins.

Authors:  L Hegedüs; W J van der Vijgh; I Klein; S Kerpel-Fronius; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Determination of cis-diamminedichloroplatinum (II) in plasma proteins and hemoglobin of cancer patients.

Authors:  R Mustonen; P Hietanen; S Leppälä; M Takala; K Hemminki
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

3.  Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration.

Authors:  Hans Ehrsson
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Ultrasound image-guided therapy enhances antitumor effect of cisplatin.

Authors:  Noboru Sasaki; Nobuki Kudo; Kensuke Nakamura; Sue Yee Lim; Masahiro Murakami; W R Bandula Kumara; Yu Tamura; Hiroshi Ohta; Masahiro Yamasaki; Mitsuyoshi Takiguchi
Journal:  J Med Ultrason (2001)       Date:  2013-07-17       Impact factor: 1.314

5.  Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Shape changes induced by N-terminal platination of ubiquitin by cisplatin.

Authors:  Jonathan P Williams; Hazel I A Phillips; Iain Campuzano; Peter J Sadler
Journal:  J Am Soc Mass Spectrom       Date:  2010-02-11       Impact factor: 3.109

7.  Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-05-06       Impact factor: 3.466

8.  Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck.

Authors:  J D Holding; W E Lindup; C van Laer; G C Vreeburg; V Schilling; J A Wilson; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

9.  Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma.

Authors:  J Z Fuks; M J Egorin; J Aisner; D A Van Echo; S Ostrow; N R Bachur; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.